- Home
- DENN vs DRUG Comparison
DENN vs DRUG Comparison
Compare DENN & DRUG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DENN
- DRUG
- Stock Information
- Founded
- DENN 1953
- DRUG 2019
- Country
- DENN United States
- DRUG United States
- Employees
- DENN N/A
- DRUG N/A
- Industry
- DENN Restaurants
- DRUG Pharmaceuticals and Biotechnology
- Sector
- DENN Consumer Discretionary
- DRUG Health Care
- Exchange
- DENN Nasdaq
- DRUG Nasdaq
- Market Cap
- DENN 211.7M
- DRUG 199.7M
- IPO Year
- DENN 1989
- DRUG N/A
- Fundamental
- Price
- DENN $4.81
- DRUG $43.95
- Analyst Decision
- DENN Strong Buy
- DRUG Strong Buy
- Analyst Count
- DENN 7
- DRUG 8
- Target Price
- DENN $6.96
- DRUG $83.60
- AVG Volume (30 Days)
- DENN 636.3K
- DRUG 68.6K
- Earning Date
- DENN 10-21-2025
- DRUG 08-11-2025
- Dividend Yield
- DENN N/A
- DRUG N/A
- EPS Growth
- DENN N/A
- DRUG N/A
- EPS
- DENN 0.30
- DRUG N/A
- Revenue
- DENN $455,727,000.00
- DRUG N/A
- Revenue This Year
- DENN $7.57
- DRUG N/A
- Revenue Next Year
- DENN $1.89
- DRUG N/A
- P/E Ratio
- DENN $15.85
- DRUG N/A
- Revenue Growth
- DENN 0.06
- DRUG N/A
- 52 Week Low
- DENN $2.85
- DRUG $0.94
- 52 Week High
- DENN $7.73
- DRUG $79.02
- Technical
- Relative Strength Index (RSI)
- DENN 67.51
- DRUG 60.50
- Support Level
- DENN $4.31
- DRUG $38.00
- Resistance Level
- DENN $4.61
- DRUG $45.00
- Average True Range (ATR)
- DENN 0.21
- DRUG 3.22
- MACD
- DENN 0.05
- DRUG -0.46
- Stochastic Oscillator
- DENN 98.89
- DRUG 70.50
About DENN Denny's Corporation
Denny's Corp is America's franchised full-service restaurant chains based on the number of restaurants. The company owns and operates the Denny's brand and the Keke's Breakfast Cafe brand. It provides Pancakes, Appetizers & Soups, Sandwiches & Salads, Breakfast Melts, Omelets, and others. The company generates its revenue from two sources: the sale of food and beverages and the collection of royalties, advertising revenue, initial and other fees, including occupancy revenue, from restaurants operated by their franchisees. Geographically operates in USA states as well as globally like Canada, Mexico, Guatemala, Indonesia, United Kingdom, New Zealand and others. Maximum revenue is from USA and Canada.
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.